Abstract
Virotherapy is currently being developed for many different types of viruses including replication-competent murine leukaemia virus (MLV) as a novel tool in cancer therapy. However, there is the risk of insertional mutagenesis associated with this virus, making careful preclinical studies necessary before its first application in man. We have previously generated conditionally replication-competent MLV variants that require activation by tumour-associated proteases to become infectious. Here we analysed in a comparative study the spreading of non-targeted and of such tumour-targeted MLV variants to tumour and extratumoural organs in immunodeficient mice. Both virus types were able to efficiently infect tumour cells after systemic administration. The non-targeted virus, however, also infected extratumoural organs like bone marrow, spleen and liver efficiently. In contrast, the targeted viruses revealed in a quantitative analysis of virus spreading an up to 500-fold more selective infection of tumour tissue than the non-targeted virus. The data raise serious doubts about a safe clinical use of non-targeted MLV. Engineering the virus to become activatable by tumour-associated proteases can significantly improve the safety of MLV.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dalba C, Klatzmann D, Logg CR, Kasahara N . Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther 2005; 5: 655–667.
Solly SK, Trajcevski S, Frisen C, Holzer GW, Nelson E, Clerc B et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 2003; 10: 30–39.
Logg CR, Kasahara N . Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo. Methods Mol Biol 2004; 246: 499–525.
Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N . A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 2001; 12: 921–932.
Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N . Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol 2002; 76: 12783–12791.
Wang WJ, Tai CK, Kasahara N, Chen TC . Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003; 14: 117–127.
Metzl C, Mischek D, Salmons B, Gunzburg WH, Renner M, Portsmouth D . Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J Virol 2006; 80: 7070–7078.
Finger C, Sun Y, Sanz L, Alvarez-Vallina L, Buchholz CJ, Cichutek K . Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Ther 2005; 12: 464–474.
Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ . Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 2005; 12: 900–912.
Wang W, Tai CK, Kershaw AD, Solly SK, Klatzmann D, Kasahara N et al. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 2006; 20: E25.
Hiraoka K, Kimura T, Logg CR, Tai CK, Haga K, Lawson GW et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007; 67: 5345–5353.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419.
Lopez-Otin C, Overall CM . Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002; 3: 509–519.
Schneider RM, Medvedovska Y, Hartl I, Voelker B, Chadwick MP, Russell SJ et al. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Therapy 2003; 10: 1370–1380.
Hartl I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russell SJ et al. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. 2005; 12: 918–926.
Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ . In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 1998; 16: 951–954.
Szecsi J, Drury R, Josserand V, Grange MP, Boson B, Hartl I et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 2006; 14: 735–744.
Springfeld C, von MV, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R . Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006; 66: 7694–7700.
Morling FJ, Peng KW, Cosset FL, Russell SJ . Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 1997; 234: 51–61.
Buchholz CJ, Duerner LJ, Funke S, Schneider IC . Retroviral display and high throughput screening. Comb Chem High Throughput Screen 2008; 11: 99–110.
Wilkinson DA, Mager DL, Leong JAC . Endogenous human retroviruses. In: Levy JA (ed). The Retroviridae. Plenum Press: New York and London, 1994, pp 465–466.
Becker M, Nitsche A, Neumann C, Aumann J, Junghahn I, Fichtner I . Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer 2002; 87: 1328–1335.
Tai CK, Wang WJ, Chen TC, Kasahara N . Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005; 12: 842–851.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–256.
Gaspar HB, Thrasher AJ . Gene therapy for severe combined immunodeficiencies. Expert Opin Biol Ther 2005; 5: 1175–1182.
Kohn DB, Sadelain M, Glorioso JC . Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477–488.
Puente XS, Sanchez LM, Overall CM, Lopez-Otin C . Human and Mouse Proteases: A Comparative Genomic Approach. Nat Rev Genet 2003; 4: 544–558.
Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 1998; 111 (Part 18): 2789–2798.
Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B et al. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 2003; 199: 517–525.
Acknowledgements
We thank Yuansheng Sun, Cheick Coulibaly and Roland Plesker for supervising animal experimentation, Julia Medvedovska for excellent technical assistance and Christine Hohenadl for critical reading of the paper. This work was supported by grant 107743 of the Deutsche Krebshilfe and grant 01GU0504 of the Bundesministerium für Bildung und Forschung (BMBF) to C.J.B.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)
Supplementary information
Rights and permissions
About this article
Cite this article
Duerner, L., Schwantes, A., Schneider, I. et al. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue. Gene Ther 15, 1500–1510 (2008). https://doi.org/10.1038/gt.2008.92
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2008.92
Keywords
This article is cited by
-
Tumor-specific suicide gene therapy for hepatocellular carcinoma by transcriptionally targeted retroviral replicating vectors
Gene Therapy (2015)
-
Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression
Molecular Therapy (2012)
-
RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors
Gene Therapy (2011)
-
Selective gene silencing by viral delivery of short hairpin RNA
Virology Journal (2010)
-
VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
Gene Therapy (2010)